Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Novo narrowed its full-year guidance for the fourth time this year, saying it now expects sales growth within the range of 8% ...

Revenue was down 5.9% from last year to $16.654, after increasing 10% the previous quarter. These results were better than ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

The new offer from Novo Nordisk constitutes a superior company proposal, Metsera says.

The battle for control of a promising obesity drug maker has intensified, with one pharmaceutical giant upping its bid to $10 ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...

Pfizer sues Metsera and Novo Nordisk for breaching merger agreement and seeks injunction to enforce deal after ...